Top
image credit: Adobe Stock

Drugmakers Look to Curb Medicare’s New Power to Negotiate Lower Drug Prices

Drugmakers are trying to blunt Medicare’s newfound power to negotiate medicine prices while coping with internal industry disputes and ebbing influence in Washington, D.C.

Under the Inflation Reduction Act, Congress gave Medicare, the country’s biggest buyer of prescription drugs, the authority to negotiate how much it pays for certain high-price therapies, and to get rebates on treatments whose prices rise more than the rate of inflation.

Drugmakers are seeking to ease the law’s impact as regulators begin to work on the details of implementing the provisions, according to people familiar with the efforts.

Read More on The Wall Street Journal